Meta-Analysis

Efficacy of Chinese herbal medicine in treatment of allergic rhinitis in children: a meta-analysis of 19 randomized controlled trials

Zhipan Zheng¹, Zhenshuang Sun¹, Xueping Zhou² and Zhongying Zhou²

Abstract
This study aimed to systematically evaluate the effect of Chinese herbal medicine (CHM) for treating allergic rhinitis in children. We reviewed relevant studies retrieved from the following databases: MEDLINE (PubMed), Embase, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, the Cqvip Database, and the Wanfang Database. The analysis was conducted by Cochrane software Revman 5.3. Nineteen randomized, controlled trials were included. Meta-analysis showed that CHM had advantages in the efficacy rate (odds ratio [OR] 3.32; 95% confidence interval [CI], 2.32–4.76), recurrence rate (OR 0.30; 95% CI, 0.18–0.49), scores of symptoms, such as sneezing (mean difference [MD] −1.24; 95% CI, −2.33 to −0.14), running nose (MD −1.32; 95% CI, −2.58 to −0.05), and nasal congestion (MD −0.70; 95% CI, −1.05 to −0.36), but not nasal itching (MD −1.37; 95% CI, −3.96 to 1.22), compared with controls. CHM could also effectively decrease immunoglobulin E levels (MD −46.01, 95% CI, −57.53 to −34.48). The current evidence suggests that CHM is more effective in treating allergic rhinitis in children compared with controls. CHM may also decrease the recurrence and level of immunoglobulin E, and improve symptoms such as sneezing, running nose, and nasal congestion, compared with controls.

¹First Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jangsu Province, China
²Nanjing University of Chinese Medicine, Jangsu Province, China

Corresponding author:
Zhongying Zhou, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Qixia District, 210023, Nanjing City, Jangsu Province, China.
Email: zzying369@126.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Allergic rhinitis (AR), which is characterized by symptoms of sneezing, rhinorrhea, nasal congestion, and nasal itching, is a type of disease of the upper respiratory tract. Studies have shown that the prevalence of AR symptoms varies from 1.5% to 24.5%. In China, the mean prevalence of childhood AR ranges from 3.9% to 16.8%. A higher prevalence of AR exists as a single entity in boys than in girls during childhood. Most patients complain of symptoms of AR before 20 years old, with 40% being symptomatic before 6 years old. Evidence has shown an association between AR and asthma in children. Although AR is not a life-threatening disease, AR imposes a heavy financial burden on patients and society because of treatment and social costs. Furthermore, AR can have a substantial negative effect on concentration and even academic performance in children.

Effective treatment is helpful in preventing children with rhinoconjunctivitis from asthma onset later in life. Treatment for AR includes effective symptomatic control, allergen avoidance, standardized immunotherapy, and health education of patients. Although medications can be effective at controlling the symptoms of nasal allergies, they are associated with adverse effects, such as local epistaxis, nasal dryness, irritation from intranasal medications, and drowsiness from antihistamines. However, growth may be hindered by use of corticosteroids. AR is a manifestation of a single inflammatory process. Immunoglobulin E (IgE) as identified by Immunological methods is considered as a diagnostic marker and therapeutic target on AR.

There is a high prevalence of Chinese traditional medicine (TCM) use in the pediatric population in China. In Taiwan, parents of children with AR tend to ask for TCM treatment and Chinese herbal medicine (CHM) as the most common therapeutic approach. Studies have shown that CHM is effective in adults. Some clinical trials on AR in children treated with CHM have been reported. However, to the best of our knowledge, there have been no meta-analyses for evaluating the efficacy of CHM. Therefore, this systematic review aimed to collect evidence to evaluate the effect of CHM treatment of AR in children.

Methods

Database and search strategies

The literature search was conducted by two authors (Zhipan Zheng and Zhenshuang Sun) independently. Any disagreement on the relevance of inclusion was resolved by discussion until a general consensus was reached. This study did not require ethical approval because it contained data from previously published studies.

The preliminary electronic databases that we searched were MEDLINE (PubMed), Embase, Cochrane Central Register of Controlled Trials, Chinese
National Knowledge Infrastructure (CNKI), the Cqvip Database (VIP), and the Wanfang Database up to December 2017. Key words or free-text terms that we used were as follows: “allergic rhinitis”, “children”, “pediatrics”, “randomized, clinical trials”, “traditional Chinese medicine”, and “Chinese herbal medicine”.

**Inclusion criteria**

A study was eligible for inclusion if it met the following criteria: (1) a randomized, controlled trial (RCT) was designed by the study; (2) patients were diagnosed with AR as defined by the Chinese Medical Association or other well-recognized AR diagnostic criteria were included, were of either sex, and their age not older than 18 years; and (3) patients in the treatment group were treated with CHM. All RCTs were selected with no restrictions on language, population characteristics, blinding, and publication type.

**Exclusion criteria**

Studies were excluded if they met any one of the following criteria: (1) duplicated publications; (2) reviews, meeting abstracts, case reports, and comments; (3) patients whose age was older than 18 years; and (4) patients in the CHM group were treated with acupuncture, external application, or massage.

**Outcomes**

The outcome measures were as follows: (1) total effective rate (clinical cure rate + showing effectiveness rate); (2) recurrence rate; (3) scores of the symptoms, including sneezing, running nose, nasal congestion, and nasal itching; (4) IgE levels; and (5) adverse reactions.

According to the Guiding Principle of Clinical Research on New Drugs of TCM, the clinical efficacy of TCM was classified as a clinical cure, showing an effect, and no effect. A clinical cure was defined as disappearance of symptoms and signs, and no abnormal condition as checked by rhinoscopy. An effect was defined as relief of symptoms and signs, with turbinate swelling as checked by rhinoscopy. No effect was defined as no relief of symptoms and signs. Symptoms and signs included sneezing, running nose, nasal congestion, and nasal itching. Rhinoscopy was used to detect nasal mucosa with a pale color, hyperemia, turbinate swelling, and catarrh.

**Study selection and data extraction**

Two reviewers independently examined abstracts in the search results to identify potential relevance, and then screened full texts for final identification. The following information was extracted: authors, date of publication, sample size, sex and age of the participants, details of the interventions, outcomes measures, and adverse reactions. All included articles were judged by a third reviewer.

**Quality assessment**

The methodological quality of the trials was evaluated by two coauthors independently. The Jadad score criteria were used. The following three domains were assessed: method of randomization, blinding, dropouts, and withdrawals. Two points were allocated if the method of randomization was described in the study and it was appropriately conducted. One point was allocated if the method of randomization was not appropriate. Two points were allocated if the method of blinding was double-blind and the blinding method was described. One point was allocated if the method of blinding was not appropriate. One point was allocated if the study stated withdrawal or dropout. Otherwise, 0 points were allocated if the study did not describe
withdrawal and dropout. Three points or more than 3 points were considered to indicate a high-quality study. The maximum number of points was 5. Fewer than 3 points was considered to indicate a low-quality study.

**Data analysis**

Data were analyzed by using Review Manager 5.3 software (The Nordic Cochrane Centre, Copenhagen, Denmark). Heterogeneity between similar studies was evaluated by the chi-square test and $I^2$ statistic. If $I^2$ was $\leq 50\%$, then the possibility of heterogeneity between the studies was low, and a fixed-effects model was used. If $I^2$ was $>50\%$, there was heterogeneity between the studies, and a random-effects model was used. Enumeration data are expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Measurement data are expressed as the mean difference (MD) with the 95% CI. Statistical significant difference was set as $P < 0.05$. Publication bias was examined using a funnel plot by using Review Manager 5.3 software.

**Description of included studies**

An initial search identified 1149 potentially relevant citations, including 351 studies from CNKI, 372 from the Wanfang Database, 373 from VIP, 27 from PubMed, 19 from Embase, and 7 from Cochrane Central Register of Controlled Trials. A total of 555 duplicated articles were excluded using EndNote X7 software (Clarivate Analytics, Boston, MA, USA). After reading the titles and abstracts, 594 articles regarding animal experiments, experience reports, and other treatments and trials carried out on adults were eliminated. Two reviewers then carefully read the full text of the remaining 40 articles; 21 studies that did not meet all of the inclusion criteria were excluded. Therefore, 19 eligible trials were chosen for the meta-analysis. A total of 1623 participants, of which there were 832 patients in the CHM group and 791 patients in control group, were involved (Figure 1).

**Methodological quality of included RCTs**

Baseline information, such as interventions and outcome measurement, for the treatment and control groups is shown in Table 1. On the basis of the inclusion criteria, 19 relevant citations were included in this study. However, only six studies used the stochastic indicator method. The rest of the studies applied a randomized method, but none of them had a specific description. None of the studies had a precalculated sample size or used a double-blind method (Table 2).

**Meta-analysis of curing AR in children**

**Efficacy rate.** As is shown in Figure 2, 11 studies mentioned the efficacy rate difference between CHM and loratadine. A total of 956 patients were included (480 patients in the CHM group, 476 patients in the control group). The fixed-effects model was applied for statistical analysis because the 11 studies did not show heterogeneity (chi-square = 4.53, $P = 0.92$, $I^2 = 0\%$). Our analysis suggested that CHM could effectively improve the efficacy rate compared with loratadine (OR 3.32; 95% CI, 2.32–4.76; $P < 0.001$) (Figure 2).

**Scores of symptoms.** Among all 19 studies, 2 of them selected scores of the symptoms as one of their outcome measures. A total of 170 patients were included (85 patients in the CHM group, 85 patients in the control group). For the symptom of sneezing, there was statistical heterogeneity between these two clinical trials after testing for heterogeneity (chi-square = 24.78, $P < 0.001$,
Therefore, the random-effects model was used, and it showed a significant difference between the CHM and control groups (MD = -1.24; 95% CI, -2.33 to -0.14; \( P = 0.03 \)) (Figure 3a). For the symptom of a running nose, there was statistical heterogeneity between these two clinical trials after testing for heterogeneity (chi-square = 22.61, \( P < 0.001 \), \( I^2 = 96\% \)). Therefore, the random-effects model was used, and it showed a significant difference between the CHM and control groups (MD = 1.32; 95% CI, -2.58 to 0.05; \( P = 0.04 \)) (Figure 3b). For the symptom of nasal congestion, there was statistical heterogeneity between these two clinical trials after testing for heterogeneity (chi-square = 4.97, \( P = 0.03 \), \( I^2 = 80\% \)). Therefore, the random-effects model was used, and it showed a significant difference between the CHM and control groups (MD = 0.70; 95% CI, 1.05 to -0.36; \( P < 0.001 \)) (Figure 3c). For the symptom of nasal itching, there was statistical heterogeneity between these two clinical trials after testing for heterogeneity (chi-square = 29.44, \( P < 0.001 \), \( I^2 = 97\% \)). Therefore, the random-effects model was used, but it showed no significant difference between the CHM and control groups (MD = 1.37; 95% CI, -3.96 to 1.22, \( P = 0.30 \)) (Figure 3d).

**Recurrence rate.** As shown in Figure 2, five studies described the difference in recurrence rate between CHM and loratadine.\(^{34,36,38,41,46}\) A total of 405 patients were included (205 patients in the CHM group, 200 patients in the control group). The fixed-effects model was applied for statistical analysis because the five studies did not show heterogeneity (chi-square = 1.95, \( P = 0.74 \), \( I^2 = 0\% \)). The analysis showed that CHM could effectively improve the efficacy rate compared with controls (OR
| Study               | Treatment intervention        | n (M/F), age (mean ± SD and range, years) | Control intervention                  | n (M/F), age (mean ± SD and range, years) | Course (days) | Outcome measure                                      |
|---------------------|-------------------------------|------------------------------------------|---------------------------------------|------------------------------------------|----------------|-----------------------------------------------------|
| Luo et al., 2017    | Suhuang Zhike capsules        | 30, NA                                   | Loratadine tablets                    | 30, NA                                   | 14             | Efficacy, scores of the symptoms, adverse reaction  |
| Hong et al., 2017   | Decoction of CHM 60 (32/28), 5.17 ± 2.50 (2–11) | Loratadine tablets                      | 60 (29/31), 5.28 ± 2.64 (2–12)        | 28 | Efficacy                                             |
| Zhao et al., 2016   | Decoction of CHM 50, NA (3–12) | Montelukast sodium chewable tablets      | 50, NA (3–12)                         | 28 | Efficacy                                             |
| Wang et al., 2016   | Decoction of CHM 47 (25/22), 5.28 ± 1.46 (2–13) | Loratadine syrup                        | 47 (26/21), 5.34 ± 1.29 (2–12)        | 56 | Efficacy, recurrence rate                           |
| Liang, 2016         | Bimin San 32 (28/4), 9.2 ± 1.0 (5–14) | Cetirizine dihydrochloride tablets      | 28 (21/7), 8.8 ± 1.2 (6–13)           | 56 | Efficacy, adverse reaction                          |
| Hu et al., 2016     | Wenfei Zhiliu Dan 66 (35/31), 6.21 ± 1.44 (2–14) | Inhalebudesonideaerosol, Dermatophagoides farinae drops | 66 (32/34), 6.67 ± 1.26 (3–13)        | 42 | Efficacy, recurrence rate, adverse reaction         |
| Liu, 2014           | Decoction of CHM 55 (31/24), 5.17 ± 2.50 (2–11) | Loratadine syrup                        | 55 (34/21), 5.28 ± 2.64 (2–12)        | 28 | Efficacy, scores of the symptoms, adverse reaction  |
| Yu, 2015            | Decoction of CHM 48 (28/20), 6.58 ± 1.34 (4–13) | Budesonide aerosol, loratadine tablets | 48 (30/18), 6.87 ± 1.35 (3–14)        | 56 | Efficacy, recurrence rate                           |
| Zhou, 2014          | Decoction of CHM 60 (35/25), NA (2–15) | Biuyang Tongqiao granules               | 60 (31/29), NA (3–14)                | 14 | Efficacy                                             |

(continued)
| Study                  | Treatment intervention       | n (M/F), age (mean±SD and range, years) | Control intervention                                                                 | n (M/F), age (mean±SD and range, years) | Course (days) | Outcome measure          |
|-----------------------|------------------------------|----------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------|---------------|--------------------------|
| Zhang, 2014\(^{41}\) | Decoction of CHM             | 40 (23/17), NA (5–14)                 | Prednisone acetate tablets, ketotifen fumarate tablets, ephedrine hydrochloride and nitrofurazone nasal drops | 40 (24/16), NA (6–13)                  | 14            | Efficacy                 |
| Guo et al., 2014\(^{42}\) | Decoction of CHM             | 28 (15/13), NA (3.5–14)               | Loratadine tablets                                                                  | 28 (14/14), NA (3.5–14)               | 14            | Efficacy, recurrence rate |
| Chen, 2014\(^{43}\)   | Decoction of CHM             | 30 (16/14), 6.60 ± 2.12               | Loratadine tablets                                                                  | 30 (17/13), 7.20 ± 1.29               | 28            | Efficacy                 |
| Wang, 2013\(^{44}\)   | Decoction of CHM             | 50 (22/28), NA (4–14)                 | Loratadine tablets                                                                  | 50 (24/26), NA (4–12)                 | 14            | Efficacy, Scores of the symptoms |
| Luo, 2013\(^{45}\)    | Decoction of CHM             | 70 (42/28), NA (2–11)                 | Loratadine tablets                                                                  | 70 (41/29), NA (2–11)                 | 21            | Efficacy, adverse reaction |
| Wang, 2012\(^{46}\)   | Decoction of CHM             | 40 (23/17), NA (5–14)                 | Terfenadine tablets, prednisone acetate tablets, ephedrine hydrochloride nasal drops | 20 (12/8), NA (6–14)                  | 14            | Efficacy                 |
| Yang, 2010\(^{47}\)   | Yupingfeng granules          | 25 (14/11), NA (3–14)                 | Loratadine tablets                                                                  | 21 (12/9), NA (3–14)                  | 56            | Efficacy, recurrence rate |
| Chen, 2010\(^{48}\)   | Decoction of CHM             | 35 (20/15), 4.86 ± 0.43 (1.5–10)      | Loratadine tablets                                                                  | 35 (21/14), 4.76 ± 0.42 (1.8–11)      | 28            | Efficacy                 |
| Yuan et al., 2009\(^{49}\) | Bimin oral liquid         | 30 (16/14), 10.0 ± 3.5 (6–17)          | Loratadine tablets                                                                  | 30 (17/13), 11.0 ± 2.9 (5–16)         | 20            | Efficacy, IgE            |
| Zhao et al., 2006\(^{50}\) | Decoction of CHM           | 36 (19/16), NA (4–14)                 | Biyankang capsules                                                                 | 23 (13/10), NA (4.5–13)               | 10            | Efficacy, IgE            |

M: Male; F: female; CHM: Chinese herbal medicine; NA: not available; IgE: immunoglobulin E
Among the 19 studies, two of them selected IgE as one of their outcome measures.33,48 A total of 118 patients were included (65 patients in the CHM group, 53 patients in the control group). The fixed-effects model was applied for statistical analysis because the two studies did not show heterogeneity (chi-square = 1.02, \( P = 0.31, \hat{I}^2 = 2\%\)). The analysis showed that CHM could effectively decrease IgE levels compared with the control group (MD \(-46.01; 95\% \text{ CI}, -57.53 \text{ to } -34.48; P < 0.001\)) (Figure 5).
Publication bias. An “inverted funnel” pattern analysis was used to confirm publication bias. The asymmetrical figure indicated potential publication bias that might affect the results (Figure 6).

Adverse reactions. Four patients experienced skin rash in the CHM group who were treated with Wenfei Zhiliu Dan, and no other adverse reactions were reported. Adverse reactions in the control group
included drowsiness, nosebleed, fever, thirst, skin rash, and fatigue. However, calculating the incidence of adverse reactions was difficult because of insufficient adverse events reported.

**Discussion**

In this study, we systematically evaluated and analyzed previous literature on RCTs regarding the efficacy of CHM in clinical treatment of AR in children. We found that CHM could effectively improve the efficacy rate compared with loratadine. CHM may have advantages in terms of the recurrence rate and the scores of symptoms, such as sneezing, running nose, and nasal congestion, but not nasal itching. CHM may also reduce IgE levels compared with controls.

According to the TCM theory, the nose is the orifice of the lung. The pathogenicy of AR as “Feng Xie” leads to obstruction of lung-qi, which triggers symptoms, including sneezing, running nose, nasal congestion, and nasal itching. Therefore, therapeutic
methods are focused on dispelling the Feng Xie and relaxing the depressed lung-qi. This type of theory is the foundation for CHM formula on AR. The mechanism of CHM on AR may include controlling the balance of T helper 1/T helper 2, suppressing eosinophilic activity, reducing IgE levels, regulating allergenic cell degranulation, and antihistamines.51–55

There are some limitations concerning this study. First, the RCTs that were included in this study were limited and the sample sizes were small. Therefore, ruling out the influence of contingency factors is difficult. Second, the overall methodological quality of the included RCTs was not high. Although all of 19 studies stated that they used the random method, only 6 of them elaborated on the details of the stochastic method. No studies claimed a double-blind method. There was no withdrawal or dropout described. In fact, there was a high possibility of selection bias and measurement bias. Third, publication bias cannot be fully excluded without sufficient studies. In this review, an inverted funnel plot (Figure 6) showed that the publication bias might have affected the results. Some results of our study showed high heterogeneity (Figure 3). There was a high possibility of measurement bias. Finally, the intervention duration in the included articles ranged from 10 to 56 days. However, unfortunately, there is no relevant standard for the time of intervention.

Therefore, ensuring that the trials were properly conducted is difficult. Consequently, we are unable to make confirmative conclusions. High-quality, large-sample, RCTs still need to be performed in the future.

Declaration of conflicting interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Zhongying Zhou http://orcid.org/0000-0002-8916-6749

References

1. Ait-Khaled N, Pearce N, Anderson HR, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009; 64: 123–148.
2. Zhang Y and Zhang L. Prevalence of allergic rhinitis in China. Allergy Asthma Immunol Res 2014; 6: 105–113.
3. Kurukulaaratchy RJ, Karmaus W and Arshad SH. Sex and atopy influences on the natural history of rhinitis. Curr Opin Allergy Clin Immunol 2012; 12: 7–12.
4. Pinart M, Keller T, Reich A, et al. Sex-related allergic rhinitis prevalence switch from childhood to adulthood: a systematic review and meta-analysis. Int Arch Allergy Immunol 2017; 172: 224–235.
5. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001; 108: S2–S8.
6. Morais-Almeida M, Gaspar A, Pires G, et al. Risk factors for asthma symptoms at school age: an 8-year prospective study. Allergy Asthma Proc 2007; 28: 183–189.
7. Leynaert B, Neukirch F, Demoly P, et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106(5 Suppl): S201–S205.
8. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 Suppl 85: 17–25.
9. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 2009; 124: S43–S70.
10. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with
a detrimental effect on examination performance in United Kingdom teenagers: case-control study. *J Allergy Clin Immunol* 2007; 120: 381–387.

11. Simons FE. Learning impairment and allergic rhinitis. *Allergy Asthma Proc* 1996; 17: 185–189.

12. Ibero M, Justicia JL, Alvaro M, et al. Diagnosis and treatment of allergic rhinitis in children: results of the PETRA study. *Allergol Immunopathol (Madr)* 2012; 40: 138–143.

13. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2004; 114: 851–857.

14. Inal A, Alttintas DU, Yilmaz M, et al. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. *J Investig Allergol Clin Immunol* 2007; 17: 85–91.

15. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy* 2008; 63 Suppl 86: 8–160.

16. Bernstein DI, Schwartz G and Bernstein JA. Allergic rhinitis: mechanisms and treatment. *Immunol Allergy Clin North Am* 2016; 36: 261–278.

17. Bousquet J, Van Cauwenberge P, Bachert C, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). *Allergy* 2003; 58: 192–197.

18. Nurmatov U, van Schayck CP, Hurwitz B, et al. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. *Allergy* 2012; 67: 158–165.

19. Trangsrud AJ, Whitaker AL and Small RE. Intranasal corticosteroids for allergic rhinitis. *Pharmacotherapy* 2002; 22: 1458–1467.

20. Scadding GK. Intranasal steroid sprays in the treatment of rhinitis is one better than another? *J Laryngol Otol* 2004; 118: 395–396; author reply 396.

21. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. *Pediatrics* 2000; 105: E23.

22. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol* 2010; 126: 466–476.

23. Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. *Expert Rev Clin Immunol* 2015; 11: 1321–1333.

24. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. *Ann Allergy Asthma Immunol* 2003; 91: 160–167.

25. Licari A, Castagnoli R, Panfili E, et al. An update on anti-IgE therapy in pediatric respiratory diseases. *Curr Respir Med Rev* 2017; 13: 22–29.

26. Huang TP, Liu PH, Lien AS, et al. A nationwide population-based study of traditional Chinese medicine usage in children in Taiwan. *Complement Ther Med* 2014; 22: 500–510.

27. Kung YY, Chen YC, Hwang SJ, et al. The prescriptions frequencies and patterns of Chinese herbal medicine for allergic rhinitis in Taiwan. *Allergy* 2006; 61: 1316–1318.

28. Xue CC, Thien FC, Zhang JJ, et al. Treatment for seasonal allergic rhinitis by Chinese herbal medicine: a randomized placebo controlled trial. *Altern Ther Health Med* 2003; 9: 80–87.

29. Zhang X, Lan F, Zhang Y, et al. Chinese herbal medicine to treat allergic rhinitis: evidence from a meta-analysis. *Allergy Asthma Immunol Res* 2018; 10: 34–42.

30. Wang S, Tang Q, Qian W, et al. Meta-analysis of clinical trials on traditional Chinese herbal medicine for treatment of persistent allergic rhinitis. *Allergy* 2012; 67: 583–592.

31. Luo J, Yu T and Zhang M. Suhuang Zhike Capsule in the treatment of paediatric allergic rhinitis for 30 cases. *Chinese Medicine Modern Distance Education of China* 2017; 15: 94–95.
32. Hong JY, Tong LM and Huang WX. Effect of Tongqiao decoction in treating allergic rhinitis in children. *Zhejiang J Tradit Chin Med* 2017; 52: 810.

33. Zhao Y and Zheng J. Clinical observation of Yangyin Yiqi decoction in the treatment of allergic rhinitis in children. *Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine* 2016; 16: 16–18.

34. Wang XJ. Clinical effect analysis of Xiaoqinglong decoction in treating allergic rhinitis in children. *Health Care Today* 2016; 1: 164–64.

35. Liang GQ. The clinical observation of biminsan on 60 pediatric allergic rhinitis. *Journal of Chinese Ophthalmology and Otorhinolaryngology* 2016; 6: 143–144.

36. Hu TY, Xu FJ and Li S. Clinical observation of Wenfei Zhiliu Pill combined with Shenling Baizhu San in treatment of allergic rhinitis in children. *Journal of Nw Chinese Medicine* 2016; 48: 137–139.

37. Liu X. A clinical observation on Guizhi decoction for allergic rhinitis in children. *Henan Tradit Chin Med* 2014; 34: 1885–1886.

38. Yu J. Treatment of allergic rhinitis in children by TCM. *Medical Information* 2015; 28: 39–39.

39. Zhou H, Shao ZY and Lian JL. Curative effect analysis of 60 cases of pediatric allergic rhinitis treated with Shufengtongqiao decoction. *J Pedia Tradit Chin Med* 2014; 10: 48–50.

40. Zhang Y. Effect of Buzhong Yiqi decoction combined with Yuping Feng San in treatment of allergic rhinitis in children. *Medicine & People* 2014; 27: 122.

41. Guo XY and Cheng WL. Clinical observation of Biminiany decoction in treating allergic rhinitis in children. *The Journal of Medical Theory and Practice* 2014; 27: 3165–65, 66.

42. Chen QQ. Treatment of pediatric allergic rhinitis by Xiaoqinglong decoction: a clinical study. *Medical Information* 2014; 2014: 55–55, 56.

43. Wang XL. The clinical effect of Yupingfeng San combined with Guomin decoction on 50 allergic rhinitis in children. *Journal of New Chinese Medicine* 2013; 45: 80–81.

44. Luo GW. Clinical research of Qingre Tongqiao San in treating allergic rhinitis in children. *J Emerg Tradit Chin Med* 2013; 22: 2095–2096.

45. Wang JC. Treatment of allergic rhinitis in children by Wumei Cangerzi San: a clinical observation. *Traditional Chinese Medicinal Research* 2012; 25: 21–23.

46. Yang H. Clinical observation of Yupingfeng Granule in treating allergic rhinitis in children. *J Pediatrics of TCM* 2010; 6: 23–25.

47. Chen WY. 35 cases of pediatric allergic rhinitis of pulmonosplenic asthenia type treated by Gu Biao Jian Pi decoction. *China Journal of Chinese Medicine* 2010; 25: 316–317.

48. Yuan B, Han XM, Zhu XK, et al. Clinical observation of Bimin mixture in the treatment of allergic rhinitis in children. *Chinese Journal of Information on TCM* 2009; 16: 74–75.

49. Zhao XY and Gao GQ. Clinical research of Erma decoction in treating allergic rhinitis in children. *Shandong Journal of Traditional Chinese Medicine* 2006; 25: 166–167.

50. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996; 17: 1–12.

51. Yan GH, Jin GY, Li GS, et al. The possible mechanism of inhibitory effect of xanthium strumarium on mast cells activated by compound 48/80. *Progress of Anatomical Sciences* 2010; 16: 164–66 + 70.

52. Wen Z, Xu SQ, Zhou GY, et al. Effect of Bimin tablet on nasal mucosa’ histamine from the model of guinea pig allergic rhinitis. * Hunan Guiding Journal of TCM* 2002; 8: 500–502.

53. Wang SP. Effect of Mahuang Fuzi Xixin decoction on T lymphocyte subsets in allergic rhinitis. *Liaoning Journal of Traditional Chinese Medicine* 2002; 29: 562–563.

54. Pei NZ and Shu HJ. Clinical observation of Yupingfeng granule in treating allergic rhinitis. *Chin J Otorhinolaryngol Integ Med* 2003; 11: 241.

55. Huang QS, Li JM, Liu HY, et al. Clinical and experimental research of Xiao Chaihu decoction in treating allergic rhinitis. *Chin J Otorhinolaryngol Integ Med* 1996; 4: 76–78.